CLINICAL INVESTIGATOR FINANCIAL DISCLOSURE CHECK-OFF BOX PROPOSED BY HOPKINS' BLAKE; FDA BACKS TAILORING REGS TO ISOLATE MOST "PERNICIOUS" CASES
This article was originally published in The Gray Sheet
Executive Summary
Clinical investigators should disclose to FDA whether their financial involvement with a study sponsor exceeds a certain threshold, but they should not be required to make specific disclosures unless the agency so requests, Johns Hopkins Executive Vice Dean David Blake, PhD, suggested at an FDA Science Board meeting March 29.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.